Patient Recruitment Strategies for Rare Disease Clinical Trials

Recruiting patients for rare disease clinical trials is one of the hardest challenges in clinical research — and one of the most important.

By definition, a "rare disease" affects fewer than 200,000 people in the United States (or fewer than 1 in 2,000 people in Europe). That means your addressable patient population for a single trial might be measured in the hundreds — not thousands. Some ultra-rare disease trials target patient populations under 100 individuals worldwide.

When you're trying to find 30 patients out of a global population of 800, traditional recruitment tactics don't work. You can't run a Facebook ad and wait for clicks. You can't rely on a few research sites to refer patients. You need a fundamentally different approach.

This article breaks down the specific strategies that work for rare disease patient recruitment — from patient registry partnerships and genetic testing databases to global site expansion and patient advocacy collaborations. If you're planning a rare disease trial, this is your playbook.

Why Rare Disease Recruitment Is Fundamentally Different

Recruiting for a rare disease trial isn't just harder — it requires a completely different toolkit. Here's why:

The defining challenge. If your trial targets a condition affecting 500 people in the US, and only 60% meet your eligibility criteria, and only 40% live near a study site, and only 50% of those agree to participate — you're enrolling 24 patients. From a population of 500. Every patient matters, and every drop-off is catastrophic.

Rare disease patients are spread across the country — and the globe. You can't rely on a single research center or region. Patients may need to travel hundreds of miles for a study visit, which adds transportation, lodging, and caregiver burden to the recruitment challenge.

Many rare disease patients are undiagnosed or misdiagnosed. A study in Genetics in Medicine found that the average rare disease patient sees 7.3 physicians over 4.8 years before receiving a correct diagnosis. Some of your eligible patients may not even know what condition they have yet.

Because the condition is rare, there may be little patient education material available. Patients may not understand the disease, the treatment landscape, or what clinical trial participation involves. Education is a prerequisite to enrollment.

Rare disease patients and their families are often desperate for treatment options. This can drive high motivation to participate — but it also means you need to be especially careful about informed consent, expectation setting, and ethical communication.

Strategy 1: Partner with Patient Registries and Natural History Studies

Patient registries are databases of patients who have been diagnosed with a specific condition and have agreed to be contacted about research. They are one of the most effective recruitment channels for rare disease trials.

How it works: - Rare disease registries are often maintained by patient advocacy organizations (e.g., the National Organization for Rare Disorders, Eurodis, or disease-specific foundations) - Patients voluntarily share their diagnosis, demographics, and contact information - When a trial launches, the registry can send recruitment announcements to matching patients

Why it works for rare disease: - Registry patients are already diagnosed — eliminating the diagnostic gap - They've opted in to research contact — they're pre-interested - Registries are disease-specific — you're reaching exactly the patients you need - Registry platforms may also support natural history studies that generate data you can use for recruitment planning

How to get started: 1. Identify relevant patient registries for your disease area (search rarediseases.org, orphanet.org, or disease-specific foundations) 2. Contact the registry operator to discuss recruitment collaboration 3. Develop a recruitment announcement that the registry can distribute to matching patients 4. Ensure your IRB protocol allows for registry-sourced referrals

Strategy 2: Leverage Genetic Testing and Diagnostic Databases

For genetic rare diseases, genetic testing labs and diagnostic databases are a powerful recruitment channel. Patients who have undergone genetic testing and received a relevant diagnosis are prime candidates for trials targeting that genetic condition.

How it works: - Genetic testing companies (e.g., Invitae, Color Health, GeneDx) maintain databases of tested patients - Some companies offer "match" programs that connect diagnosed patients with relevant clinical trials - The testing company contacts matching patients (with their consent) to let them know about trial opportunities

Why it works for rare disease: - Genetic confirmation eliminates diagnostic uncertainty - You can target patients with specific genetic variants that match your trial's inclusion criteria - Patients who have undergone genetic testing are already engaged with their health data

Considerations: - Genetic testing partnerships require careful attention to privacy, consent, and HIPAA compliance - Not all testing companies offer trial matching — but the number is growing - Some registries and advocacy groups maintain their own genetic databases

Strategy 3: Build Patient Advocacy Organization Partnerships

Patient advocacy organizations are often the most trusted voice in a rare disease community. They understand the patient experience, have established communication channels, and can lend credibility to your trial.

How to partner effectively: - Identify relevant organizations: Look for disease-specific foundations, rare disease alliances, and patient groups - Engage early: Don't wait until your trial is enrolling to reach out. Involve advocacy groups during trial design to ensure the protocol is patient-friendly - Provide value: Offer to fund patient education materials, sponsor community events, or support the organization's programs - Be transparent: Share trial details, timelines, and what participation involves. Advocacy groups are protective of their communities — respect that - Ask for guidance: Advocacy organizations know their communities better than anyone. Ask them what messaging works, what concerns patients have, and what barriers to participation exist

Why it works: - Advocacy organizations have direct, trusted relationships with patients - They can distribute recruitment messaging through newsletters, social media, community events, and support groups - Their endorsement lends credibility that no ad campaign can match - They can provide feedback on protocol feasibility from the patient perspective

Strategy 4: Expand Geographic Reach and Enable Travel

Because rare disease patients are geographically dispersed, you need a recruitment strategy that reaches across state lines — and often across borders.

Global site expansion: - Consider sites in multiple countries to increase your addressable patient pool - European sites can access patients in countries with concentrated rare disease populations - Work with CROs that have global site networks to accelerate activation

Travel support programs: - Offer transportation reimbursement, lodging stipends, or travel coordination for patients who live far from study sites - Consider decentralization elements — home health visits, telemedicine, or local lab draws — to reduce the number of required site visits - Build travel logistics into your recruitment budget from the start

Remote and decentralized trial elements: - Telemedicine screening visits reduce the need for patients to travel for initial assessments - Home-based visits (through companies like Science 37 or thread) bring the trial to the patient - Electronic consent (eConsent) allows patients to review and sign consent documents remotely - Wearables and digital monitoring can reduce the frequency of on-site visits

For rare diseases specifically, decentralization can be the difference between enrolling 15 patients and enrolling 30.

Strategy 5: Use Targeted Digital Advertising — the Right Way

Digital advertising still has a role in rare disease recruitment, but it requires a fundamentally different approach than common-condition trials.

What works for rare disease: - Condition-specific targeting: Target patients who search for the specific disease name, related symptoms, or treatment options - Caregiver targeting: Many rare disease patients are children. Target parents and caregivers who search for the condition - Physician targeting: Reach specialists who treat the condition (geneticists, neurologists, metabolic specialists) - Patient forum and community advertising: Place ads on rare disease forums, Facebook groups, and patient community platforms - Retargeting: Patients who visit your trial landing page but don't convert should see follow-up ads reminding them of the opportunity

What doesn't work: - Generic "clinical trial" advertising — the audience is too broad and unqualified - Broad condition targeting (e.g., "neurological disorders") — too many irrelevant patients - High-volume ad strategies — rare disease requires precision, not volume

Strategy 6: Engage Referring Physicians and Specialists

For rare diseases, the diagnosing physician is often the first — and most trusted — touchpoint for patients. Engaging these specialists is critical.

How to build physician referral networks: - Identify physicians who diagnose or treat your target condition (search medical society directories, pubmed for published authors, and NORD's physician guides) - Reach out with a concise, scannable trial summary — not a 20-page protocol document - Provide patient referral materials the physician can hand to eligible patients - Offer to present at specialty conferences or department grand rounds - Make the referral process easy — provide a direct contact line or referral form

Why this matters for rare disease: - Patients trust their diagnosing physician more than any ad - Physicians can identify patients who may not be in registries or databases - A warm referral from a trusted physician dramatically increases the likelihood of participation

Harry Hunter

Director of Patient Recruitment Strategy

Specializing in protocol-matched patient acquisition, multi-site enrollment operations, and pre-screening workflows for clinical trials

Harry Hunter on LinkedIn